Literature DB >> 27796500

Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP).

José María Pelayo-Terán1,2, Virginia Gajardo Gajardo Galán3,4, Víctor de la Ortiz-García de la Foz3,5, Obdulia Martínez-García3,5, Rafael Tabarés-Seisdedos5,6, Benedicto Crespo-Facorro3,5, Rosa Ayesa-Arriola3,5.   

Abstract

Relapses may represent a critical hazard in schizophrenia spectrum disorders as they are associated with an increased risk of a clinical and functional deterioration. Preventing relapse after recovering from a first psychotic episode has become a major challenge due to its critical impact on lifelong functionality. This study explored the rate of first and second relapses and the predictors associated with these relapses in a large cohort of non-affective psychosis patients during a period of 3 years after the first break of the illness. From February 2001 to May 2014, sociodemographic and clinical data from an epidemiological cohort of 341 non-affective first-episode psychosis patients at risk of relapse were analysed at a specialized early intervention service. Logistic regression, Cox regression, and Kaplan-Meier survival analyses were performed to compare non-relapsed and relapsed patients. One hundred and sixty-six (48.7%) individuals relapsed at least once. Median time to relapse was 17.0 months in non-adherent patients and 40.0 months in adherent patients (log-rankχ 2: 51.36; p < 0.001). Non-adherence to medication (odds ratio-OR 2.979; p < 0.001), schizophrenia diagnosis (OR 2.173; p = 0.002), and age of onset (OR 1.020; p = 0.033) were the main predictors of the first relapse. Fifty-six subjects experienced a second relapse (33.73%) predicted by diagnosis (OR 1.975; p = 0.074), age of onset (OR 1.078; p = 0.003), and positive symptoms (OR 0.863; p = 0.03), but not adherence. Non-adherence is the main predictive factor of first relapse after a first episode of psychosis. Second relapses were not often and not related to modifiable factors, suggesting that multiple relapsed patients may comprise a subgroup with a higher biological risk.

Entities:  

Keywords:  Adherence; First-episode psychosis; Longitudinal studies; Relapse; Schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 27796500     DOI: 10.1007/s00406-016-0740-3

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  33 in total

1.  Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine.

Authors:  Benedicto Crespo-Facorro; Rocío Pérez-Iglesias; Ignacio Mata; Olalla Caseiro; Obdulia Martínez-Garcia; Gema Pardo; Mariluz Ramirez-Bonilla; Jose Maria Pelayo-Terán; José L Vázquez-Barquero
Journal:  J Psychiatr Res       Date:  2010-11-23       Impact factor: 4.791

Review 2.  Treatment strategies to prevent relapse and encourage remission.

Authors:  John M Kane
Journal:  J Clin Psychiatry       Date:  2007       Impact factor: 4.384

3.  Factors influencing relapse during a 2-year follow-up of first-episode psychosis in a specialized early intervention service.

Authors:  A Malla; R Norman; L Bechard-Evans; N Schmitz; R Manchanda; C Cassidy
Journal:  Psychol Med       Date:  2008-01-21       Impact factor: 7.723

4.  Relationship between relapse and hospitalization in first-episode psychosis.

Authors:  Donald Emile Addington; Scott B Patten; Emily McKenzie; Jean Addington
Journal:  Psychiatr Serv       Date:  2013-08-01       Impact factor: 3.084

5.  A 3-year retrospective cohort study of predictors of relapse in first-episode psychosis in Hong Kong.

Authors:  Christy L-M Hui; Jennifer Y-M Tang; Chung-Ming Leung; Gloria H-Y Wong; Wing-Chung Chang; Sherry K-W Chan; Edwin H-M Lee; Eric Y-H Chen
Journal:  Aust N Z J Psychiatry       Date:  2013-04-23       Impact factor: 5.744

6.  Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder.

Authors:  D G Robinson; M G Woerner; J M Alvir; S Geisler; A Koreen; B Sheitman; M Chakos; D Mayerhoff; R Bilder; R Goldman; J A Lieberman
Journal:  Am J Psychiatry       Date:  1999-04       Impact factor: 18.112

7.  Assessment of premorbid function in first-episode schizophrenia: modifications to the Premorbid Adjustment Scale.

Authors:  Sarah van Mastrigt; Jean Addington
Journal:  J Psychiatry Neurosci       Date:  2002-03       Impact factor: 6.186

8.  Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort.

Authors:  D Wiersma; F J Nienhuis; C J Slooff; R Giel
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

Review 9.  Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies.

Authors:  M Alvarez-Jimenez; A Priede; S E Hetrick; S Bendall; E Killackey; A G Parker; P D McGorry; J F Gleeson
Journal:  Schizophr Res       Date:  2012-06-01       Impact factor: 4.939

10.  Medication adherence of individuals with a first episode of psychosis.

Authors:  E L Coldham; J Addington; D Addington
Journal:  Acta Psychiatr Scand       Date:  2002-10       Impact factor: 6.392

View more
  7 in total

1.  Improving outcomes of first-episode psychosis: an overview.

Authors:  Paolo Fusar-Poli; Patrick D McGorry; John M Kane
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

2.  Early childhood social communication deficits in youth at clinical high-risk for psychosis: Associations with functioning and risk.

Authors:  K Juston Osborne; Teresa Vargas; Vijay A Mittal
Journal:  Dev Psychopathol       Date:  2020-05

3.  Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT.

Authors:  Andrew I Gumley; Simon Bradstreet; John Ainsworth; Stephanie Allan; Mario Alvarez-Jimenez; Maximillian Birchwood; Andrew Briggs; Sandra Bucci; Sue Cotton; Lidia Engel; Paul French; Reeva Lederman; Shôn Lewis; Matthew Machin; Graeme MacLennan; Hamish McLeod; Nicola McMeekin; Cathy Mihalopoulos; Emma Morton; John Norrie; Frank Reilly; Matthias Schwannauer; Swaran P Singh; Suresh Sundram; Andrew Thompson; Chris Williams; Alison Yung; Lorna Aucott; John Farhall; John Gleeson
Journal:  Health Technol Assess       Date:  2022-05       Impact factor: 4.106

4.  Risk factors of hospitalization for any medical condition among patients with prior emergency department visits for mental health conditions.

Authors:  Louise Penzenstadler; Lia Gentil; Guy Grenier; Yasser Khazaal; Marie-Josée Fleury
Journal:  BMC Psychiatry       Date:  2020-09-03       Impact factor: 3.630

5.  Early Signs Monitoring to Prevent Relapse in Psychosis and Promote Well-Being, Engagement, and Recovery: Protocol for a Feasibility Cluster Randomized Controlled Trial Harnessing Mobile Phone Technology Blended With Peer Support.

Authors:  Andrew Gumley; Simon Bradstreet; John Ainsworth; Stephanie Allan; Mario Alvarez-Jimenez; Louise Beattie; Imogen Bell; Max Birchwood; Andrew Briggs; Sandra Bucci; Emily Castagnini; Andrea Clark; Sue M Cotton; Lidia Engel; Paul French; Reeva Lederman; Shon Lewis; Matthew Machin; Graeme MacLennan; Claire Matrunola; Hamish McLeod; Nicola McMeekin; Cathrine Mihalopoulos; Emma Morton; John Norrie; Frank Reilly; Matthias Schwannauer; Swaran P Singh; Lesley Smith; Suresh Sundram; David Thomson; Andrew Thompson; Helen Whitehill; Alison Wilson-Kay; Christopher Williams; Alison Yung; John Farhall; John Gleeson
Journal:  JMIR Res Protoc       Date:  2020-01-09

6.  Psychosis Relapse Prediction Leveraging Electronic Health Records Data and Natural Language Processing Enrichment Methods.

Authors:  Dong Yun Lee; Chungsoo Kim; Seongwon Lee; Sang Joon Son; Sun-Mi Cho; Yong Hyuk Cho; Jaegyun Lim; Rae Woong Park
Journal:  Front Psychiatry       Date:  2022-04-05       Impact factor: 5.435

7.  Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.

Authors:  Marcos Gómez-Revuelta; José María Pelayo-Terán; María Juncal-Ruiz; Javier Vázquez-Bourgon; Paula Suárez-Pinilla; Rodrigo Romero-Jiménez; Esther Setién Suero; Rosa Ayesa-Arriola; Benedicto Crespo-Facorro
Journal:  Int J Neuropsychopharmacol       Date:  2020-04-23       Impact factor: 5.176

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.